Hematologic Oncology

Dr Short discusses data in acute lymphoblastic leukemia that were presented at the 2023 ASCO Annual Meeting and EHA Congress.

Although the highly potent, selective, allosteric, oral, small molecule BRG1/BRM inhibitor FHD-286 elicited signs of clinical activity and safety as monotherapy in patients with metastatic uveal melanoma in the dose-escalation portion of a phase 1 trial, further development in this indication will not be pursued.

Expert oncologists discuss management strategies for patients with lower-risk MDS considering upcoming treatment options.

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.

Oncologists review study design and discuss key safety and efficacy data of the COMMANDS trial investigating luspatercept in frontline setting in patients with lower-risk MDS.

Funda Meric-Bernstam, MD, discusses a first-in-human phase 1/2 study of CBX-12 in patients with advanced or metastatic solid tumors.

Paolo Ghia, MD, PhD, reviews data from the ELEVATE-RR trial investigating acalabrutinib versus ibrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

The FDA has granted an orphan drug designation to the novel, highly potent, and selective MDM2 degrader KT-253 for the treatment of patients with acute myeloid leukemia.

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Epcoritamab elicited a confirmed overall response rate of 82% by independent review committee assessment in patients with relapsed or refractory follicular lymphoma who received 2 or more prior systemic treatments, which exceeded the prespecified threshold for efficacy in the phase 1/2 EPCORE NHL-1 trial.

Ryan Jacobs, MD, expands on the initial efficacy and safety data seen with TNB-486, the need for more data on treatment-related CRS to improve toxicity management, and next steps planned for the investigation of this and other bispecific antibodies in relapsed/refractory follicular lymphoma.

Fixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lymphoma, according to updated data from the phase 2 GO29781 trial.

Harry Gill, MD, FRCP, FRCPath, discusses updated efficacy data and analysis of genomic characteristics for ropeginterferon alfa-2B in primary myelofibrosis.

Pau Montesinos, MD, PhD, discusses the preliminary results of the QUIWI trial, expands on the potential implications for the use of quizartinib plus chemotherapy in newly diagnosed patients with FLT3-ITD–negative acute myeloid leukemia, and details the next steps for this study and future research.

The addition of zanubrutinib to obinutuzumab produced superior clinical activity, prolonged survival, and had a favorable toxicity profile compared with obinutuzumab alone in heavily pretreated patients with relapsed/refractory follicular lymphoma.

Greg Roloff, MD, reviews data on the outcomes of patients with relapsed/refractory B-ALL who received treatment with brexucabtagene autoleucel.

The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor.

Single-agent treatment with the CDK9 inhibitor AZD4573 produced clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma.

Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma, including patients with disease progression after transplant or CAR T-cell therapy, and as a category 2A preferred regimen for patients with histologic transformation of indolent lymphoma to DLBCL with no intention to proceed to transplant, including patients with disease progression after transplant or CAR T-cell therapy.

John M. Burke, MD, expands on the use of novel BTK inhibitor regimens in mantle cell lymphoma, treatment sequencing challenges and other unmet needs in diffuse-large B-cell lymphoma, the evolution of management strategies for myeloproliferative neoplasms, and the potential influence of new and emerging therapeutics in chronic lymphocytic leukemia.

The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial.